UPDATE: Morgan Stanley Reiterates on Allscripts Healthcare Solutions as Momentum will Continue in 2014
In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), and raised the price target from $20.00 to $21.00.
In the report, Morgan Stanley noted, “Allscripts is a diversified HCIT vendor for hospitals, physician practices, and other healthcare providers. New leadership has solidified the existing customer base with increased product quality, investment in R&D, and product roadmap. Leadership position in growing area of Population Health through strategic acquisition of dbMotion. Replacement of EHR systems ahead of Meaningful Use Stage 2 provides an opportunity from both legacy MDRX and implementation of dbMotion. Compelling valuation – trades at a steep discount to HCIT peers.”
Allscripts Healthcare Solutions closed on Thursday at $17.22.
Latest Ratings for MDRX
|Dec 2016||Dougherty||Initiates Coverage On||Neutral|
|Nov 2016||Deutsche Bank||Downgrades||Buy||Hold|
|Oct 2016||JP Morgan||Assumes||Overweight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.